Table 1. Clinical and genetic characteristics of three cases assessed by follow-up study.

Patient number.	Age	Gender	Histological type	p-Stage	Residual tumour after surgery	Gene mutation 1	Gene mutation 2	Postoperative chemotherapy	Metastasis site, number, timing	Treatment for metastasis	Responsea
4	86	Male	Differentiated	IIIC	R0	TP53 c.103delT	PIK3CA c.1633G>A	Yes	Liver, single, POD275	Chemotherapy	SD
5	73	Male	Differentiated	IVb	R1	TP53 c.747G>C	PIK3CA c.1633G>A	Yes	Liver, multiple, POD93	Chemotherapy molecular-target drug	PD
8	80	Male	Differentiated	IVc	R2	TP53 c.166G>T	FBXW7 c.1177C>T	No	Liver, multiple, (residue)	None	PD

Abbreviations: PD=progressive disease; POD=postoperative day; R1=microscopic residual tumour; R2=macroscopic residual tumour; R0=no residual tumour (curative resection); SD=stable disease.

^aAccording to the Response Evaluation Criteria in Solid Tumors (RECIST).

^bPeritoneal cytology positive for carcinoma cells, and

^cHepatic metastasis.